Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Primary Target

Cytochrome P450 24A1

6

Histamine H1 receptor

316

Dopamine D2 receptor

311

DNA

282

Serotonin 2a (5-HT2a) receptor

237

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

4

Other

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1978

4

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Hypocalcemia

4

Mild to moderate plaque psoriasis

4

Secondary hyperparathyroidism

4

Unknown

4

Cancer

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

5

Preventing

4

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Myrtle, J.F.|Haussler, M.R.|Norman, A.W.

4

Jones, G. et al.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

6

FDA UNII

6

PUBCHEM

6

EPA CompTox

3

CHEBI

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

1

DERMATOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIPSORIATICS

1

VITAMINS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIPSORIATICS FOR TOPICAL USE

1

VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other antipsoriatics for topical use

1

Vitamin D and analogues

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

3

Salts, Hydrates, Esters, etc.

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 6 of 6 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CALCITRIOL

FXC9231JVH

Export Data
Search for Structure

Status:

US Approved Rx (1998)

First approved in 1978

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Vitamin D3 receptor

Cytochrome P450 24A1

Cytochrome P450 3A4

Conditions:

Mild to moderate plaque psoriasis

Secondary hyperparathyroidism

Calcitriol is vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Calcitriol is used to treat hyperparathyroidism (overactive parathyroid glands) and metabolic bone disease...

in people who have chronic kidney failure and are not receiving dialysis. Calcitriol is also used to treat calcium deficiency (hypocalcemia). The early signs and symptoms of vitamin D intoxication associated with hypercalcemia include: weakness, headache, somnolence, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain and metallic taste. Cholestyramine has been reported to reduce intestinal absorption of fatsoluble vitamins; as such it may impair intestinal absorption of Calcitriol. Ketoconazole may inhibit both synthetic and catabolic enzymes of calcitriol.

1,25-DIHYDROXYCALCIFEROL

5RWP08OQ36

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Vitamin D receptor

Cytochrome P450 24A1

Conditions:

1,25-dihydroxycalciferol (1,25-dihydroxyvitamin D2 or ercalcitriol) is a metabolite of vitamin D. It exerts antirachitic activity in animals. 1,25-dihydroxycalciferol and its analogs have antineoplastic actions in vitro.

VID-400

A53Q3K00XS

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Cytochrome P450 24A1

3.BETA.-D-GLUCOPYRANOSYLCALCITRIOL

4HF9ADM3YJ

Export Data
Search for Structure

Status:

US Approved Rx (1998)

First approved in 1978

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Vitamin D3 receptor

Cytochrome P450 24A1

Cytochrome P450 3A4

Conditions:

Mild to moderate plaque psoriasis

Secondary hyperparathyroidism

Calcitriol is vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Calcitriol is used to treat hyperparathyroidism (overactive parathyroid glands) and metabolic bone disease...

in people who have chronic kidney failure and are not receiving dialysis. Calcitriol is also used to treat calcium deficiency (hypocalcemia). The early signs and symptoms of vitamin D intoxication associated with hypercalcemia include: weakness, headache, somnolence, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain and metallic taste. Cholestyramine has been reported to reduce intestinal absorption of fatsoluble vitamins; as such it may impair intestinal absorption of Calcitriol. Ketoconazole may inhibit both synthetic and catabolic enzymes of calcitriol.

TRANS-CALCITRIOL

I1L29CLX3C

Export Data
Search for Structure

Status:

US Approved Rx (1998)

First approved in 1978

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Vitamin D3 receptor

Cytochrome P450 24A1

Cytochrome P450 3A4

Conditions:

Mild to moderate plaque psoriasis

Secondary hyperparathyroidism

Calcitriol is vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Calcitriol is used to treat hyperparathyroidism (overactive parathyroid glands) and metabolic bone disease...

in people who have chronic kidney failure and are not receiving dialysis. Calcitriol is also used to treat calcium deficiency (hypocalcemia). The early signs and symptoms of vitamin D intoxication associated with hypercalcemia include: weakness, headache, somnolence, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain and metallic taste. Cholestyramine has been reported to reduce intestinal absorption of fatsoluble vitamins; as such it may impair intestinal absorption of Calcitriol. Ketoconazole may inhibit both synthetic and catabolic enzymes of calcitriol.

CALCITRIOL MONOHYDRATE

97SK7L66LH

Export Data
Search for Structure

Status:

US Approved Rx (1998)

First approved in 1978

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Vitamin D3 receptor

Cytochrome P450 24A1

Cytochrome P450 3A4

Conditions:

Mild to moderate plaque psoriasis

Secondary hyperparathyroidism

Calcitriol is vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Calcitriol is used to treat hyperparathyroidism (overactive parathyroid glands) and metabolic bone disease...

in people who have chronic kidney failure and are not receiving dialysis. Calcitriol is also used to treat calcium deficiency (hypocalcemia). The early signs and symptoms of vitamin D intoxication associated with hypercalcemia include: weakness, headache, somnolence, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain and metallic taste. Cholestyramine has been reported to reduce intestinal absorption of fatsoluble vitamins; as such it may impair intestinal absorption of Calcitriol. Ketoconazole may inhibit both synthetic and catabolic enzymes of calcitriol.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1